SG11201400205QA - Selective and reversible inhibitors of ubiquitin specific protease 7 - Google Patents

Selective and reversible inhibitors of ubiquitin specific protease 7

Info

Publication number: SG11201400205QA
Authority: SG; Singapore
Prior art keywords: selective; specific protease; reversible inhibitors; ubiquitin specific; ubiquitin
Prior art date: 2011-09-02

Application number

SG11201400205QA

Inventor

Frédéric Colland

Marie-Edith Gourdel

Original Assignee

Hybrigenics Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-02

Filing date

2012-08-29

Publication date

2014-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46750347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201400205Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-29 Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa

2014-03-28 Publication of SG11201400205QA publication Critical patent/SG11201400205QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SG11201400205QA 2011-09-02 2012-08-29 Selective and reversible inhibitors of ubiquitin specific protease 7 SG11201400205QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11306096A EP2565186A1 (en)	2011-09-02	2011-09-02	Selective and reversible inhibitors of ubiquitin specific protease 7
PCT/EP2012/066741 WO2013030218A1 (en)	2011-09-02	2012-08-29	Selective and reversible inhibitors of ubiquitin specific protease 7

Publications (1)

Publication Number	Publication Date
SG11201400205QA true SG11201400205QA (en)	2014-03-28

Family

ID=46750347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201400205QA SG11201400205QA (en)	2011-09-02	2012-08-29	Selective and reversible inhibitors of ubiquitin specific protease 7

Country Status (24)

Country	Link
US (1)	US9546150B2 (en)
EP (2)	EP2565186A1 (en)
JP (1)	JP6059228B2 (en)
KR (1)	KR20140085430A (en)
CN (1)	CN103930415B (en)
AR (1)	AR087757A1 (en)
AU (1)	AU2012300944B2 (en)
BR (1)	BR112014004649A2 (en)
CA (1)	CA2847017A1 (en)
CL (1)	CL2014000511A1 (en)
DK (1)	DK2751092T3 (en)
ES (1)	ES2594603T3 (en)
HU (1)	HUE029418T2 (en)
IL (1)	IL231203A (en)
LT (1)	LT2751092T (en)
MA (1)	MA35361B1 (en)
MX (1)	MX340500B (en)
PL (1)	PL2751092T3 (en)
PT (1)	PT2751092T (en)
RU (1)	RU2622640C2 (en)
SG (1)	SG11201400205QA (en)
SI (1)	SI2751092T1 (en)
TN (1)	TN2014000079A1 (en)
WO (1)	WO2013030218A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7
CA2896731A1 (en)	2012-12-28	2014-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN105327350A (en) *	2014-07-23	2016-02-17	中国科学院上海巴斯德研究所	Application of ubiquitin pathway related factor in regulating function of helper T cells
MA41291A (en)	2014-12-30	2017-11-07	Forma Therapeutics Inc	PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
TWI698436B (en)	2014-12-30	2020-07-11	美商佛瑪治療公司	Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en)	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) *	2015-02-05	2018-02-15	フォーマセラピューティクス，インコーポレイテッド	Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
JP2018504430A (en)	2015-02-05	2018-02-15	フォーマセラピューティクス，インコーポレイテッド	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
CN105251020B (en) *	2015-09-29	2018-10-09	武汉大学	Ubiquitin-specific protease 4（USP4）Function in treating myocardial hypertrophy and application
GB201522267D0 (en) *	2015-12-17	2016-02-03	Mission Therapeutics Ltd	Novel compounds
GB201602854D0 (en) *	2016-02-18	2016-04-06	Mission Therapeutics Ltd	Novel compounds
GB201604647D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
GB201604638D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
FR3061177B1 (en) *	2016-12-28	2019-09-27	Les Laboratoires Servier	NOVEL HETERO (ARYL) -SUBSTITUTED PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
JP6985299B2 (en)	2016-06-10	2021-12-22	レラボラトワールセルヴィエ	A novel (hetero) aryl substituted piperidinyl derivative, a process for preparing it, and a pharmaceutical composition containing it.
FR3052451B1 (en) *	2016-06-10	2018-06-22	Les Laboratoires Servier	NOVEL PIPERIDINYL HETERO DERIVATIVES (ARYL) -SUBSTITUES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3052452B1 (en) *	2016-06-10	2018-06-22	Les Laboratoires Servier	NOVEL PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
EP3481803B1 (en)	2016-07-08	2020-09-02	Mayo Foundation for Medical Education and Research	Methods and materials for treating cancer
GB201612938D0 (en) *	2016-07-26	2016-09-07	Almac Discovery Ltd	Pharmaceutical compounds
GB201616511D0 (en)	2016-09-29	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201616627D0 (en)	2016-09-30	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201617758D0 (en)	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
WO2018081897A1 (en) *	2016-11-03	2018-05-11	Trillium Therapeutics Inc.	Enhancement of cd47 blockade therapy by proteasome inhibitors
GB201708652D0 (en)	2017-05-31	2017-07-12	Mission Therapeutics Ltd	Novel compounds and uses
JP7208931B2 (en)	2017-06-20	2023-01-19	ミッションセラピューティクスリミティド	Substituted cyanopyrrolidines with activity as DUB inhibitors
CA3072353A1 (en) *	2017-09-26	2019-04-04	Dana-Farber Cancer Institute, Inc.	Novel usp7 inhibitors for treating multiple myeloma
GB201801562D0 (en) *	2018-01-31	2018-03-14	Almac Diagnostics Ltd	Pharmaceutical compounds
EP3870179A4 (en) *	2018-10-22	2022-11-23	Dana Farber Cancer Institute, Inc.	Usp7 inhibition
BR112021010644A2 (en) *	2018-12-06	2021-09-28	Almac Discovery Limited	COMPOUND, STEREOISOMER, TAUTOMER, HYDRATE, N-OXIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF OBESITY, INSULIN RESISTANCE, TYPE II DIABETES, MUSCLE ATROPHY AND CANCER AND FOR REDUCTION OF MUSCLE MASS LOSS IN AN INDIVIDUAL , AND, USP19 INHIBITOR
US20220125760A1 (en)	2019-02-14	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
GB201905371D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
GB201905375D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
WO2021009209A1 (en) *	2019-07-15	2021-01-21	Oncoarendi Therapeutics S.A.	Substituted amino triazoles useful as chitinase inhibitors
GB201912674D0 (en)	2019-09-04	2019-10-16	Mission Therapeutics Ltd	Novel compounds
CN113087718B (en) *	2020-01-09	2024-02-09	四川科伦博泰生物医药股份有限公司	Thienopyrimidinone compounds and medical application thereof
GB202001980D0 (en)	2020-02-13	2020-04-01	Almac Discovery Ltd	Therapeutic mentods
CN115427076B (en) *	2020-02-28	2025-01-03	免疫学有限公司	Human deubiquitinase inhibitors for the treatment of coronavirus infection
MX2022012578A (en)	2020-04-08	2022-11-07	Mission Therapeutics Ltd	N-cyanopyrrolidines with activity as usp30 inhibitors.
EP4157332A4 (en) *	2020-05-26	2024-06-05	Lowell Therapeutics, Inc.	METHODS OF TREATING VIRUS INFECTIONS WITH PROTEASE INHIBITORS
BR112022020644A2 (en)	2020-05-28	2022-12-06	Mission Therapeutics Ltd	N-(1-CYANO-PYRROLIDIN-3-IL)-5-(3-(TRIFLUOROMETHYL)PHENYL) OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION
IL298710A (en)	2020-06-04	2023-02-01	Mission Therapeutics Ltd	N-cyanopyrrolidines with activity as USP30 inhibitors
US20230312580A1 (en)	2020-06-08	2023-10-05	Mission Therapeutics Limited	1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
CN112047933B (en) *	2020-10-15	2022-06-14	郑州大学	Quinazolinone USP7 inhibitor and preparation method and application thereof
GB202016800D0 (en)	2020-10-22	2020-12-09	Mission Therapeutics Ltd	Novel compounds
EP4441044A1 (en)	2021-12-01	2024-10-09	Mission Therapeutics Limited	Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
GB202200753D0 (en)	2022-01-21	2022-03-09	Almac Discovery Ltd	Pharmaceutical compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2796417A (en) *	1952-04-03	1957-06-18	American Cyanamid Co	Quinazolone compounds and methods of making the same
US3073826A (en) *	1960-10-20	1963-01-15	Mead Johnson & Co	3-pyrrolidylmethyl-4-quinazolones
WO1993012795A1 (en) *	1985-08-30	1993-07-08	Glazer Edward A	Quinazolin-4(3h)-one derivatives as anticoccidial agents
FI95572C (en)	1987-06-22	1996-02-26	Eisai Co Ltd	Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
US7842522B2 (en)	2001-10-19	2010-11-30	Applied Nanotech Holdings, Inc.	Well formation
AR046787A1 (en) *	2003-12-05	2005-12-21	Bristol Myers Squibb Co	HETEROCICLIC ANTIMIGRAN AGENTS
SE0303280D0 (en)	2003-12-05	2003-12-05	Astrazeneca Ab	Novel compounds
US8084459B2 (en)	2004-04-02	2011-12-27	Prana Biotechnology Ltd	Substituted quinazolinones for treating neurological conditions
SE0401656D0 (en)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
WO2006012577A2 (en) *	2004-07-22	2006-02-02	Bayer Pharmaceuticals Corporation	Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
AU2005278959A1 (en)	2004-08-31	2006-03-09	Astrazeneca Ab	Quinazolinone derivatives and their use as B-Raf inhibitors
WO2006072048A2 (en)	2004-12-30	2006-07-06	The Trustees Of Princeton University	Compositions and methods for identifying modulators of hausp
US7709516B2 (en)	2005-06-17	2010-05-04	Endorecherche, Inc.	Helix 12 directed non-steroidal antiandrogens
EP1749822B1 (en)	2005-08-05	2008-10-15	Hybrigenics S.A.	Novel cysteine protease inhibitors and their therapeutic applications
WO2007030366A1 (en)	2005-09-06	2007-03-15	Smithkline Beecham Corporation	Regioselective process for preparing benzimidazole thiophenes
ES2474865T3 (en) *	2006-06-22	2014-07-09	Prana Biotechnology Limited	Method of treating a glioma brain tumor
US20080188498A1 (en) *	2007-02-05	2008-08-07	Radix Pharmaceuticals, Inc.	Pyridopyrimidinone compounds with antimalarial activity
EP2331525A4 (en) *	2008-08-11	2013-01-02	Harvard College	HALOFUGINONE ANALOGUES FOR THE INHIBITION OF ARNT SYNTHÉTASES AND USES THEREOF
WO2010051245A1 (en)	2008-11-03	2010-05-06	Merck Sharp & Dohme Corp.	Benzimidazole and aza-benzimidazole carboxamides
US20110177105A1 (en)	2010-01-15	2011-07-21	Roman Lopez	Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7

2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/en not_active Withdrawn
2012
- 2012-08-29 PT PT127510808T patent/PT2751092T/en unknown
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/en active Active
- 2012-08-29 US US14/241,923 patent/US9546150B2/en not_active Expired - Fee Related
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/en active Application Filing
- 2012-08-29 CA CA2847017A patent/CA2847017A1/en not_active Abandoned
- 2012-08-29 PL PL12751080T patent/PL2751092T3/en unknown
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/en not_active Expired - Fee Related
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/en not_active IP Right Cessation
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/en active Active
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-29 SI SI201230714A patent/SI2751092T1/en unknown
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/en not_active Ceased
- 2012-08-29 MX MX2014002489A patent/MX340500B/en active IP Right Grant
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/en not_active Application Discontinuation
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/en not_active Expired - Fee Related
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/en unknown
- 2012-08-31 AR ARP120103228A patent/AR087757A1/en not_active Application Discontinuation
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/en unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/en unknown

Also Published As

Publication number	Publication date
KR20140085430A (en)	2014-07-07
US20140371247A1 (en)	2014-12-18
BR112014004649A2 (en)	2017-03-14
EP2751092B1 (en)	2016-07-27
AR087757A1 (en)	2014-04-16
AU2012300944A1 (en)	2014-03-20
CN103930415A (en)	2014-07-16
JP6059228B2 (en)	2017-01-11
NZ621827A (en)	2016-07-29
TN2014000079A1 (en)	2015-07-01
PL2751092T3 (en)	2017-01-31
AU2012300944B2 (en)	2017-06-01
CN103930415B (en)	2017-05-24
WO2013030218A4 (en)	2013-04-25
MX340500B (en)	2016-07-11
RU2622640C2 (en)	2017-06-19
EP2565186A1 (en)	2013-03-06
IL231203A0 (en)	2014-04-30
WO2013030218A1 (en)	2013-03-07
ES2594603T3 (en)	2016-12-21
US9546150B2 (en)	2017-01-17
JP2014527064A (en)	2014-10-09
CA2847017A1 (en)	2013-03-07
MA35361B1 (en)	2014-08-01
RU2014112692A (en)	2015-10-10
HUE029418T2 (en)	2017-02-28
PT2751092T (en)	2016-11-04
LT2751092T (en)	2016-10-25
MX2014002489A (en)	2014-11-14
CL2014000511A1 (en)	2014-12-05
EP2751092A1 (en)	2014-07-09
IL231203A (en)	2017-04-30
DK2751092T3 (en)	2016-10-10
SI2751092T1 (en)	2016-10-28

Publication	Publication Date	Title
SG11201400205QA (en)	2014-03-28	Selective and reversible inhibitors of ubiquitin specific protease 7
SI2523938T1 (en)	2014-12-31	Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
GB201103526D0 (en)	2011-04-13	Selective glycosidase inhibitors and uses thereof
EP2678018A4 (en)	2015-09-30	Combination of kanase inhibitors and uses thereof
EP2663312A4 (en)	2014-10-22	Irak inhibitors and uses thereof
HK1198827A1 (en)	2015-06-12	Dyrk1 inhibitors and uses thereof dyrk1
HK1216248A1 (en)	2016-10-28	Plasminogen activator-1 inhibitors and methods of use thereof -1
HK1201207A1 (en)	2015-08-28	Acc inhibitors and uses thereof acc
ZA201307499B (en)	2015-09-30	Compositions and methods comprising serine protease variants
HK1191016A1 (en)	2014-07-18	Selective glycosidase inhibitors and uses thereof
ZA201304937B (en)	2014-03-26	Plasminogen and plasmin variants
IL231270A0 (en)	2014-04-30	Kynurenine-3-monooxygenase inhibitors, pharmaceutical composiitons, and methos of use thereof
IL230821A0 (en)	2014-03-31	Plasminogen and plasmin variants
IL230705A0 (en)	2014-03-31	Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
ZA201307956B (en)	2015-01-28	Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
ZA201301795B (en)	2014-05-28	Inhibitors of notum pectinacetylesterase and methods of their use
HK1199252A1 (en)	2015-06-26	Inhibitors of nedd8-activating enzyme nedd8-
EP2697246A4 (en)	2015-01-07	Selective cysteine protease inhibitors and uses thereof
SI2655388T1 (en)	2016-10-28	Selective glycosidase inhibitors and uses thereof
GB201409877D0 (en)	2014-07-16	Composition pharmaceutical composition of protease inhibitors and production thereof
GB201010084D0 (en)	2010-07-21	Cysteine protease inhibitors
GB201120387D0 (en)	2012-01-11	Cysteine protease inhibitor salt
GB201120378D0 (en)	2012-01-11	Cysteine protease inhibitor salt
AU2011900234A0 (en)	2011-02-10	Serine protease inhibitors